173 filings
Page 6 of 9
8-K
wh2p qsfvnbisjrzdwbt
11 Jun 19
BioPharmX Reports Fiscal First Quarter 2020 Financial Results
4:14pm
8-K
0qpuirr
16 May 19
Entry into a Material Definitive Agreement
5:06pm
8-K
o4ihmya01w
26 Apr 19
BioPharmX Completes 1-for-25 Reverse Stock Split
4:05pm
8-K
yk3rmwvixx ur0lwsazc
25 Mar 19
Departure of Directors or Certain Officers
8:29am
8-K
7dbe4pk
21 Mar 19
BioPharmX Announces $3.9 Million Offering
4:16pm
8-K
jppa0v
14 Mar 19
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results
4:07pm
8-K
lyd52folxpr4w5
27 Feb 19
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
4:27pm
8-K
bkxey6k6c ras8co
4 Feb 19
BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott
5:22pm
8-K
ol9jph6l8lhfk
20 Dec 18
BioPharmX Receives Notice of Noncompliance from NYSE American
4:40pm
8-K
lz2xl3m8nz
6 Dec 18
BioPharmX Reports Third Quarter 2019 Financial Results
4:15pm
8-K
1gi25ehqfxd9j90c
21 Nov 18
Entry into a Material Definitive Agreement
8:30am
8-K
xylicidiuajg7
2 Nov 18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:00am
8-K
ogdrond19gx7dmwad7m5
31 Oct 18
Entry into a Material Definitive Agreement
4:10pm
8-K
tp3725s3wn gy7
11 Oct 18
BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea
4:38pm
8-K
ifetbkrkm9
28 Sep 18
BioPharmX Receives Notice of Noncompliance from NYSE American
9:16am
8-K
dnhoz2f
13 Sep 18
BioPharmX Corporation Announces David S. Tierney, MD Joined the Company as Chief Executive Officer
12:00am
8-K
0b4psjtpk21q6vtb
30 Aug 18
BioPharmX Reports Second Quarter 2019 Financial Results
12:00am
8-K
u6a rrxoa1m8enxnqmf
17 Aug 18
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
a9dmiuwt8ra
7 Jun 18
BioPharmX Reports First Quarter 2019 Financial Results
5:07pm
8-K
2txiy
26 Apr 18
BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results
4:16pm